Back to Journals » Drug Design, Development and Therapy » Volume 8

Does fesoterodine have a role in the treatment of poorly managed patients with overactive bladder?

Authors Morris V, Wagg A

Received 18 October 2013

Accepted for publication 13 November 2013

Published 9 January 2014 Volume 2014:8 Pages 113—119

DOI https://doi.org/10.2147/DDDT.S40032

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Vikky Morris,1 Adrian Wagg2

1Geriatric Medicine, Taunton Hospital Somerset, UK; 2Division of Geriatric Medicine, University of Alberta, Edmonton, Alberta, Canada

Abstract: Overactive bladder (OAB), a clinically defined symptom complex comprising urinary urgency, usually accompanied by urinary frequency and nocturia, with or without urgency incontinence, is common and has a markedly negative impact on the sufferer's quality of life. Following conservative and lifestyle management, the current pharmacological mainstay of treatment is antimuscarinic therapy. This review explores the role of fesoterodine, a relatively recently introduced antimuscarinic agent, in the treatment of patients who may have had a suboptimal response to initial therapy, who have switched treatment from tolterodine, or may be at risk of receiving poor treatment because of either multimorbidity or complex polypharmacy.

Keywords: elderly, fesoterodine, overactive bladder, urgency incontinence

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]